Catheter Ablation Versus Radio-Ablation for Ventricular Tachycardia: a Randomized Controlled Trial
Recruiting
Phase 3
Interventional Study
Ventricular Tachycardia
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 55 and older
- Sex
- Any
- Trial phase
- Phase 3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 244 (estimated)
- Sponsor
- Ottawa Heart Institute Research Corporation · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This study compares two arms - the current standard of care catheter ablation for Ventricular Tachycardia compared to stereotactic radiotherapy to non-invasively ablate ventricular tachycardia using a novel non-invasive ECG based body surface mapping technology. This allows investigators to identify ventricular tachycardia circuits to target for subsequent radio ablation. To summarize, the current…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Patient aged ≥55 years of age
2. Cardiomyopathy (Left ventricular ejection fraction ≤ 35% and ICD in situ) AND
3. Recurrent VT events despite previous CA OR
4. VT events requiring intervention and PAINESD score ≥ 15
Exclusion Criteria:
1. Patients with NYHA Class IV heart f…
Contacts